<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Fresenius Se &amp; Co. Kgaa — News on 6ix</title>
    <link>https://6ix.com/company/fresenius-se-and-co-kgaa</link>
    <description>Latest news and press releases for Fresenius Se &amp; Co. Kgaa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 09 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/fresenius-se-and-co-kgaa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836045f78dffbe2df1357a1.webp</url>
      <title>Fresenius Se &amp; Co. Kgaa</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa</link>
    </image>
    <item>
      <title>CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/cms-grants-fresenius-kabi-covid-19-indication-specific-hcpcs-codes-for-tyenner-tocilizumab-aazg</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/cms-grants-fresenius-kabi-covid-19-indication-specific-hcpcs-codes-for-tyenner-tocilizumab-aazg</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
      <description>LAKE ZURICH, Ill., April 09, 2026--Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for Medicare &amp; Medicaid Services has issued indication-specific Healthcare Common Procedure Coding System (HCPCS) codes for Tyenne® (tocilizumab-aazg) for the treatment of COVID-19. The new codes will be effective for Medicare claims for eligible patients administered Tyenne on April 1, 2026.</description>
    </item>
    <item>
      <title>Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabi-tq-therapeutics-announce-cell-therapy-technology-agreement</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabi-tq-therapeutics-announce-cell-therapy-technology-agreement</guid>
      <pubDate>Wed, 14 Jan 2026 13:00:00 GMT</pubDate>
      <description>LAKE ZURICH, Ill., January 14, 2026--Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing.</description>
    </item>
    <item>
      <title>Fresenius Kabi Introduces First-Ever Rocuronium Bromide Injection Stable at Room Temperature</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabi-introduces-first-ever-rocuronium-bromide-injection-stable-at-room-temperature</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabi-introduces-first-ever-rocuronium-bromide-injection-stable-at-room-temperature</guid>
      <pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
      <description>LAKE ZURICH, Ill., December 18, 2025--Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has launched Rocuronium Bromide Injection Room Temperature Stable (RTS), the first formulation of Rocuronium Bromide Injection that does not require refrigeration.</description>
    </item>
    <item>
      <title>mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/mabxience-and-hp-drive-the-use-of-artificial-intelligence-in-biomanufacturing-and-biosimilar-development-1</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/mabxience-and-hp-drive-the-use-of-artificial-intelligence-in-biomanufacturing-and-biosimilar-development-1</guid>
      <pubDate>Thu, 04 Dec 2025 08:00:00 GMT</pubDate>
      <description>mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution that optimizes the production process of monoclonal antibodies and biosimilars.</description>
    </item>
    <item>
      <title>Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabis-adaptive-nomogram-used-on-aurora-xi-plasmapheresis-system-now-operating-nationwide-at-biolife-plasma-centers</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabis-adaptive-nomogram-used-on-aurora-xi-plasmapheresis-system-now-operating-nationwide-at-biolife-plasma-centers</guid>
      <pubDate>Wed, 12 Nov 2025 22:30:00 GMT</pubDate>
      <description>LAKE ZURICH, Ill., November 12, 2025--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today the successful completion of the U.S. rollout of the Adaptive Nomogram technology used on its Aurora Xi Plasmapheresis System across BioLife Plasma Services’ network of plasma donation centers. The implementation, which began in March 2025 in a phased approach, has been completed ahead of schedule, marking a</description>
    </item>
    <item>
      <title>FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence® and Bomyntra® (denosumab-bnht)</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/fda-grants-interchangeable-designation-to-fresenius-kabis-biosimilars-conexxencer-and-bomyntrar-denosumab-bnht</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/fda-grants-interchangeable-designation-to-fresenius-kabis-biosimilars-conexxencer-and-bomyntrar-denosumab-bnht</guid>
      <pubDate>Wed, 29 Oct 2025 19:56:00 GMT</pubDate>
      <description>LAKE ZURICH, Ill., October 29, 2025--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the U.S. Food and Drug Administration (FDA) designated Conexxence®(1) and Bomyntra®(2) (denosumab-bnht) as interchangeable biosimilars to the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively.</description>
    </item>
    <item>
      <title>Fresenius Kabi Receives Two Major Awards for Supply and Service Excellence from Vizient®</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabi-receives-two-major-awards-for-supply-and-service-excellence-from-vizientr</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabi-receives-two-major-awards-for-supply-and-service-excellence-from-vizientr</guid>
      <pubDate>Thu, 25 Sep 2025 15:00:00 GMT</pubDate>
      <description>LAKE ZURICH, Ill., September 25, 2025--Fresenius Kabi, part of the global healthcare company Fresenius, announced today it has received two Service Excellence awards from Vizient®, the nation’s largest provider-driven healthcare performance improvement company.</description>
    </item>
    <item>
      <title>Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-leads-new-easygen-consortium-aimed-at-decentralizing-car-t-cell-therapy-and-improving-hospital-workflows</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-leads-new-easygen-consortium-aimed-at-decentralizing-car-t-cell-therapy-and-improving-hospital-workflows</guid>
      <pubDate>Tue, 26 Aug 2025 18:31:00 GMT</pubDate>
      <description>BAD HOMBURG, Germany, August 26, 2025--The global healthcare company Fresenius is collaborating with other companies and academic institutions with the goals of accelerating the manufacturing of CAR-T cell therapy, making it more cost-effective, and improving patient access across Europe. Led by Fresenius, the newly launched EASYGEN (Easy workflow integration for gene therapy) consortium will focus on efforts to develop a modular, hospital-based platform capable of manufacturing personalized cel</description>
    </item>
    <item>
      <title>Fresenius Kabi Receives 2025 Premier Supplier Legacy Award</title>
      <link>https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabi-receives-2025-premier-supplier-legacy-award</link>
      <guid isPermaLink="true">https://6ix.com/company/fresenius-se-and-co-kgaa/news/fresenius-kabi-receives-2025-premier-supplier-legacy-award</guid>
      <pubDate>Thu, 17 Jul 2025 13:26:00 GMT</pubDate>
      <description>LAKE ZURICH, Ill., July 17, 2025--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company.</description>
    </item>
  </channel>
</rss>